Optimization of the Antibacterial Spectrum and the Developability Profile of the Novel-Class Natural Product Corramycin.
Stephane RenardStéphanie VersluysThomas TaillierNelly DubarryCorinne Leroi-GeisslerAstrid ReyEmilie CornaireSylvie SordelloJean-Christophe B CarryOdile Angouillant-BonifaceThierry GouyonFabienne ThompsonGilles LebourgVictor CertalLaszlo BalazsEsther ArranzGilles DoerflingerFrancois BretinVincent GervatEric BrohanVolker KraftXavier BoulencCécile DucelierEric BacquéCedric CouturierPublished in: Journal of medicinal chemistry (2023)
Corramycin 1 is a novel zwitterionic antibacterial peptide isolated from a culture of the myxobacterium Corallococcus coralloides . Though Corramycin displayed a narrow spectrum and modest MICs against sensitive bacteria, its ADMET and physchem profile as well as its high tolerability in mice along with an outstanding in vivo efficacy in an Escherichia coli septicemia mouse model were promising and prompted us to embark on an optimization program aiming at enlarging the spectrum and at increasing the antibacterial activities by modulating membrane permeability. Scanning the peptidic moiety by the Ala-scan strategy followed by key stabilization and introduction of groups such as a primary amine or siderophore allowed us to enlarge the spectrum and increase the overall developability profile. The optimized Corramycin 28 showed an improved mouse IV PK and a broader spectrum with high potency against key Gram-negative bacteria that translated into excellent efficacy in several in vivo mouse infection models.
Keyphrases
- escherichia coli
- mouse model
- silver nanoparticles
- computed tomography
- clinical trial
- adipose tissue
- randomized controlled trial
- molecular docking
- open label
- metabolic syndrome
- anti inflammatory
- insulin resistance
- multidrug resistant
- skeletal muscle
- mass spectrometry
- molecular dynamics simulations
- staphylococcus aureus
- wound healing
- high fat diet induced
- double blind
- biofilm formation